3rd Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 20, 2010 $90,000 Replaced
3rd Quarter - Report Jan 20, 2011 $80,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to biosimilar approval pathway, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents

LobbyistCovered position, as disclosed
JOFF MASUKAWA —

Medicare/Medicaid MMM

End Stage Renal Disease (ESRD) bundling and non-injectable oral equivalents;

LobbyistCovered position, as disclosed
JOFF MASUKAWA —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.